Nicox Edison Group Nicox is a french pharmaceutical company seeking to become an ophthalmology specialist. its core nitric oxide donating platform creates new versions of existing drugs. Nicox develops innovative therapeutics to help maintain vision and improve ocular health.
Nicox Edison Group Nicox is an international ophthalmic r&d company, aiming to build a diversified portfolio of therapeutic products addressing the needs of eyecare practitioners and patients around the world. Nicox develops drugs for eye diseases, with lead candidate ncx 470 in phase iii trials targeting the topical treatment of glaucoma by utilising and expanding on an already established dual iop lowering mechanistic approach. Nicox has a highly experienced leadership team. their combined expertise, from leading pharmaceutical and biotech companies, covers research, clinical development, regulatory, finance, business and corporate development, alliance management and communication. Nicox is on track to file for approval of its ncx 470 therapy for eyesight robbing disease glaucoma after it showed efficacy in a second pivotal trial.
Nicox Executive Interview Edison Group Nicox has a highly experienced leadership team. their combined expertise, from leading pharmaceutical and biotech companies, covers research, clinical development, regulatory, finance, business and corporate development, alliance management and communication. Nicox is on track to file for approval of its ncx 470 therapy for eyesight robbing disease glaucoma after it showed efficacy in a second pivotal trial. Find company research, competitor information, contact details & financial data for nicox inc of dallas, tx. get the latest business insights from dun & bradstreet. Business description based in france, nicox develops therapeutics for the treatment of ocular conditions. lead development candidate ncx 470 is in phase iii studies for the treatment of glaucoma. nicox also receives licence revenue from its partners for its fda approved drugs vyzulta and zerviate. Nicox develops therapeutics for the treatment of ocular conditions, with lead candidate ncx 470 in phase iii development for the topical ocular treatment of glaucoma. France based nicox develops therapeutics for the treatment of ocular conditions. its lead candidate ncx 470 is in phase iii studies for the treatment of glaucoma and it is advancing ncx 4251 for dry eye disease. nicox also receives licence revenue for its fda approved drugs vyzulta and zerviate.
Comments are closed.